Ryzil Pharmaceuticals Private Limited
About Ryzil Pharmaceuticals Private Limited
Data last updated:
Ryzil Pharmaceuticals Private Limited was a private limited company based in Moradabad, Uttar Pradesh, India. The company has been struck off by the Registrar of Companies, typically due to non-filing of annual returns or failure to commence business. It is no longer operational and cannot enter into any legal contracts or agreements. It operated in the service-based operations segment of the business services sector. It was incorporated on 18 August 2017.
The company was registered with the Registrar of Companies (ROC), Kanpur, under CIN U74999UP2017PTC096057.
The company had an authorised share capital of ₹1 Lakh and a paid-up capital of ₹1 Lakh. It was led by directors Mohd Shahnawaz and Shubham Rathi.
Its last annual general meeting (AGM) was held on 15 November 2018, and its latest financial statements are for the year ended 31 March 2018. The registered office was at 3B/15 Budhi Vihar Behind Kundan Petrol Pamp Delhi Road, Moradabad, Uttar Pradesh, India – 244001.
As per the financials filed for FY 2018, the company reported a revenue of ₹5.28 Lakh. For the same year it recorded a net loss of ₹2.05 Lakh (net margin -38.8%) and EBITDA of -₹2.05 Lakh (EBITDA margin -38.7%).
Company details
Contact details
Ryzil Pharmaceuticals Private Limited's registered office is in Moradabad, Uttar Pradesh.
- Registered Address3B/15 Budhi Vihar Behind Kundan Petrol Pamp Delhi Road, Moradabad, Uttar Pradesh, India – 244001
- IndustryBusiness Services, Other Services, Miscellaneous Business Activities
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
Business activity
The main business activity of Ryzil Pharmaceuticals is trade. In detail, this covers wholesale trading.
| Main activity group code | Main activity | Business activity code | Business activity | Share of turnover |
|---|---|---|---|---|
| G | Trade | G1 | Wholesale Trading |
To see the full business activity and turnover split of Ryzil Pharmaceuticals Private Limited, buy the company report.
Financials of Ryzil Pharmaceuticals Private Limited
FY 2018 filings availableRyzil Pharmaceuticals Private Limited reported revenue of ₹5.28 Lakh for FY 2018.
Financial Statement Summary
| Metrics | FY 2017-18 |
|---|---|
| Profit and Loss Statement | |
| Revenue from Operations | |
| Other Income | |
| Total Revenue | |
| Cost of Materials Consumed | |
| Employee Benefit Expense | |
| Finance Costs | |
| Depreciation and Amortisation | |
| Other Expenses | |
| Total Expenses | |
| EBITDA | -₹2.05 Lakh |
| Profit Before Tax | |
| Tax Expense | |
| Net Profit (PAT) | -₹2.05 Lakh |
| Balance Sheet | |
| Share Capital | |
| Reserves and Surplus | |
| Net Worth (Total Equity) | |
| Long-term Borrowings | |
| Short-term Borrowings | |
| Trade Payables | |
| Total Liabilities | |
| Fixed Assets | |
| Investments | |
| Inventories | |
| Trade Receivables | |
| Cash and Bank Balance | |
| Total Assets | |
Financial Ratios
| Metrics | FY 2017-18 |
|---|---|
| Profitability | |
| EBITDA Margin | -38.7% |
| Net Profit Margin | -38.8% |
| Return on Equity (ROE) | |
| Return on Capital Employed (ROCE) | |
| Return on Assets (ROA) | |
| Liquidity and Debt | |
| Current Ratio | |
| Quick Ratio | |
| Debt-to-Equity Ratio | |
| Interest Coverage Ratio | |
| Efficiency and Growth | |
| Asset Turnover | |
| Receivable Days | |
| Payable Days | |
| Inventory Days | |
| Revenue Growth | |
| Net Profit Growth | |
To see the full financial statements and ratios of Ryzil Pharmaceuticals Private Limited, buy the company report.
Board of directors of Ryzil Pharmaceuticals Private Limited
Ryzil Pharmaceuticals has 2 directors on record. No former directors are listed.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Mohd Shahnawaz | Director | 18 Aug 2017 | 9 Years 2 Months | As last reported |
| Shubham Rathi | Director | 18 Aug 2017 | 9 Years 2 Months | As last reported |
Peer comparison
Ryzil Pharmaceuticals Private Limited is compared with the 5 companies closest to it by revenue in the Pharma industry (Pharmaceuticals), with the same principal business activity (wholesale trading), from the latest filed financials of each company.
| Company | Revenue | Net profit | Margin | Growth (1 yr) | Employees | Location |
|---|---|---|---|---|---|---|
| Novosol Pharmaceuticals Private Limited | ₹5.33 Lakh (FY 2016) | -58.0% | Gorakhpur, Uttar Pradesh, India | |||
| Palvik Pharmaceuticals Private Limited | ₹5.32 Lakh (FY 2017) | 19.0% | Delhi, India | |||
| Medmark Pharmaceuticals Private Limited | ₹5.29 Lakh (FY 2025) | -74.0% | Kalyan, Maharashtra, India | |||
| Ryzil Pharmaceuticals Private Limitedthis company | ₹5.28 Lakh (FY 2018) | -₹2.05 Lakh | -38.8% | Moradabad, Uttar Pradesh, India | ||
| Starcia Pharmaceuticals Private Limited | ₹5.25 Lakh (FY 2025) | -21.0% | Surat, Gujarat, India | |||
| Scinder Pharmaceuticals Private Limited | ₹5.24 Lakh (FY 2023) | -10.0% | New Delhi, Delhi, India |
To see the full peer comparison of Ryzil Pharmaceuticals Private Limited, buy the company report.
Legal cases
No court or tribunal cases involving Ryzil Pharmaceuticals Private Limited are on our record; a case search with case numbers, parties and status is in the company report Buy the company report.
MSME payment delays
No delayed payments to MSME suppliers are on our record for Ryzil Pharmaceuticals Private Limited; the supplier-wise MSME Form 1 check is in the company report Buy the company report.
GST
No GST registration is on our record for Ryzil Pharmaceuticals Private Limited; the GSTIN and return-filing check is in the company report Buy the company report.
Recent activity
Ryzil Pharmaceuticals Private Limited has 2 board changes on record since 2017: 2 appointments. The latest: Mohd Shahnawaz was appointed as Director on 18 Aug 2017.
Frequently asked questions
Ryzil Pharmaceuticals has a status of "Struck Off" as per MCA records. This means the company has been officially removed from the Register of Companies, typically due to non-filing of annual returns or failure to commence business within one year of incorporation. A struck-off company cannot enter into any legal contracts or agreements, and any dealings with such an entity carry significant legal and financial risk.
Ryzil Pharmaceuticals was a private limited company based in Moradabad, Uttar Pradesh, India. The company worked in other services, within the business services industry. It was incorporated on 18 August 2017 and is registered under CIN U74999UP2017PTC096057. The company has been struck off by the Registrar of Companies and is no longer operational.
Ryzil Pharmaceuticals had 2 directors:
- Mohd Shahnawaz - Director
- Shubham Rathi - Director
The CIN (Corporate Identification Number) of Ryzil Pharmaceuticals is U74999UP2017PTC096057. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
The registered office of Ryzil Pharmaceuticals is at 3B15 Budhi Vihar Behind Kundan Petrol Pamp Delhi Road, Moradabad, Uttar Pradesh, India – 244001.
Ryzil Pharmaceuticals was incorporated on 18 August 2017. It is registered with the Registrar of Companies, Kanpur.
The latest financial statements of Ryzil Pharmaceuticals on record with the MCA are for the year ended 31 March 2018. Its last annual general meeting was held on 15 November 2018. Year-wise statements from FY 2018 are in the company report.
Ryzil Pharmaceuticals operated in the business services industry, in the other services segment. It worked in this industry before it was struck off.
The peers of Ryzil Pharmaceuticals by revenue are Novosol Pharmaceuticals Private Limited, Palvik Pharmaceuticals Private Limited, Medmark Pharmaceuticals Private Limited, Starcia Pharmaceuticals Private Limited, Scinder Pharmaceuticals Private Limited, all in the Pharma industry (Pharmaceuticals), with the same principal business activity (wholesale trading).
Mohd Shahnawaz was appointed as Director on 18 Aug 2017. Shubham Rathi was appointed as Director on 18 Aug 2017.
The compliance status of Ryzil Pharmaceuticals is compliant as of 07 July 2026.
Sample company reports
The same report you get when you buy one: financials, directors, ownership, deals, charges, legal cases, brands and filings, with the Excel workbook alongside.
